SCHEMBL4076971

SCHEMBL4076971

[CH2]c1c(OC(F)F)ccnc1OC

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 3/20 0.34
GRIN2B Q13224 3/20 0.34
RXRA P19793 2/20 0.34
TRPV4 Q9HBA0 1/20 0.34
ATP4A P20648 4/20 0.33
ATP4B P51164 4/20 0.33
ATP1A1 P05023 2/20 0.33
ATP1B1 P05026 2/20 0.33
ATP1A3 P13637 2/20 0.33
ATP1B2 P14415 2/20 0.33
ATP1A2 P50993 2/20 0.33
ATP1B3 P54709 2/20 0.33
FXYD2 P54710 2/20 0.33
ATP1A4 Q13733 2/20 0.33
HPGD P15428 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
PDE4B Q07343 3/20 0.32
GRM4 Q14833 1/20 0.32
PDE4D Q08499 3/20 0.31
PDE4A P27815 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5208664 0.87 TRPV4 (0.40) TRPV4HPGDSMN1; SMN2PDE4A
SCHEMBL4079858 0.86 TRPV4 (0.37) GRIN1GRIN2BRXRATRPV4ATP4A
SCHEMBL4069880 0.83 HPGD (0.47) GRIN1GRIN2BRXRATRPV4HPGD
SCHEMBL4074887 0.81 ALDH1A1 (0.39) HPGDSMN1; SMN2CYP1A2CYP2C9MAPK1
SCHEMBL4076975 0.81 ATP4A (0.38) GRIN1GRIN2BRXRATRPV4ATP4A
SCHEMBL188338 0.75 GRIN1 (0.48) GRIN1GRIN2BRXRATRPV4GRM4
SCHEMBL4079859 0.74 ATP4A (0.40) GRIN1GRIN2BRXRATRPV4ATP4A
SCHEMBL5208670 0.73 TRPV4 (0.40) GRIN1GRIN2BRXRATRPV4ATP4A
SCHEMBL4072808 0.69 RUNX1 (0.37) SMN1; SMN2CYP1A2CYP2C9MAPK1CYP2C19
SCHEMBL4069883 0.68 HPGD (0.49) TRPV4ATP4AATP4BATP1A1ATP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572918-B2 Prepared in high yield and high purity without the need for isolation of intermediates and chromatographic purification; useful as muscarinic receptor antagonists; 4-{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethyl)-pyrrolidin-1-yl)-hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)-piperidine THERAVANCE, INC. (US) 2009-08-11 US disclosed
US-20080091034-A1 Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds THERAVANCE, INC. 2008-04-17 US disclosed
US-7285564-B2 Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds THERAVANCE, INC. (US) 2007-10-23 US disclosed
EP-1556372-B1 SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS THERAVANCE INC (US) 2007-05-30 EP disclosed
US-20060094878-A1 Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds THERAVANCE, INC. 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094878-A1 Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds CHRM4, CHRM3, CHRM1 GRIN1 253/4885GRIN2B 421/4885RXRA 1129/4885
US-20080091034-A1 Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds CHRM5, CHRM1, CHRM3 GRIN1 411/4885GRIN2B 787/4885RXRA 969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.